Price at writing:~$10.20 (June 24, 2026; the stock has been swinging, roughly $9.20 to $13.20 over the past two months, so treat this as a moving number)
Conviction level: Medium
Key catalyst: A slow re-rating as steady growth keeps showing up, with the first read at Q2 FY2027 earnings around Sept 3, 2026. The long expiry spans roughly six earnings reports, so no single quarter makes or breaks the trade.
Why a LEAP and not a short-dated call: The whole point of the Jan 2028 expiry is time. The thesis here is "grow into the valuation," and that is a multi-quarter story, not a single-event bet. A long-dated, slightly-in-the-money call gives the business 19 months to re-rate while costing very little in daily time decay early on. The trade-off is the opposite of a momentum call: the risk is not a crash, it is dead money.
1️⃣ Trade Snapshot
The company. UiPath (PATH) sells software that automates repetitive office work for thousands of large enterprises in banking, insurance, and healthcare. Its original product is robotic process automation: small software "robots" that log into systems, move data, fill forms, and read invoices, doing the dull rules-based chores office workers used to do by hand. The newer and more important layer is agentic AI: AI agents that handle messier tasks that do not fit a rigid script, coordinated with the robots and the people who supervise them, all run through one governed, auditable platform (its Maestro product). It is a subscription business with about $1.9B of annual recurring revenue, very high (~83%) gross margins, ~$1.42B of net cash and effectively no debt, and it just turned its first full-year profit.
The trade type. Value + long-term optionality (a LEAP, a long-dated call). This is NOT a momentum or single-catalyst trade. The bet is that a profitable, cash-rich business that the market still prices like a broken 2021 IPO slowly re-rates higher as steady growth keeps showing up and the agentic-AI products convert into faster growth. The strike sits below most fair-value estimates on reported cash flow, so there is genuine valuation support underneath it.
What is this trade? You buy a call at the $10 strike expiring Jan 21, 2028, paying a premium upfront for the right to buy shares at $10. The stock is already at ~$10.20, so the call is slightly in the money (its strike sits just below the current price). It already carries a small amount of intrinsic value, about $0.20 per share; the rest of the premium is time value. The premium rises as the stock climbs (delta, the option's sensitivity to each $1 move in the stock) and decays slowly as time passes (theta). Because it is long-dated and slightly in the money, it behaves much like owning the shares with a defined maximum loss, which is exactly the point: at expiry you can either exercise it into shares (building a permanent holding) or sell the call.
Profit-taking. Scale out at price targets, not at a fixed premium percentage, because this is a multi-year hold built to either exercise or sell. Trim a portion as the stock works back toward ~$15-$16 (the base-case floor), trim materially at ~$19-$20+ (the bull-case zone), and keep a core sleeve to ride the long-run thesis. If UiPath keeps executing as expiry nears, the base plan is to exercise the calls into shares rather than just sell them, turning the leveraged bet into a permanent position.
Stop loss.NONE, by choice. This is a long-run, defined-risk hold. The most that can be lost is the premium, and a percentage stop on a volatile, slightly-in-the-money 19-month LEAP would likely trigger on normal noise (the stock swings 5-10% in a week routinely) well before the thesis has time to play out. Size the position as money you are willing to lose entirely. The discipline here is a thesis stop, not a price stop (see Section 3).
Why the timing works (the safety net). The Jan 21, 2028 expiry is long. It spans roughly six earnings reports, starting with Q2 FY2027 around Sept 3, 2026, so no single quarter makes or breaks the trade. Time decay on a 19-month, slightly-in-the-money LEAP is gentle for the first year or so and only bites hard in the final months, so holding it costs little early on. This is a hold-for-the-thesis structure, not a swing trade into one report, so there is no plan to sell into an earnings run-up.
How far does the stock need to move? It is already past the $10 strike. The trade turns a profit at expiration once the stock clears breakeven (strike plus the premium paid, TBD on the live chain). Below breakeven the call still holds intrinsic value down to $10, then expires worthless under $10. The 52-week range is $9.20 to $19.84, so at ~$10.20 the stock sits near the bottom of its own range, which is what makes the slightly-in-the-money strike cheap to own.
Key catalysts (detail in Section 5):
Agentic-AI conversion (the swing factor): AI is showing up in the large deals, and AI-attached expansion deals have reportedly run far larger than those without. If that pulls recurring-revenue growth and customer expansion back up, the whole company gets valued more generously.
Buybacks shrinking the share count: UiPath completed a $1B repurchase program and authorized another $500M, buying back stock at depressed prices, which also offsets the dilution from paying staff in stock.
A friendlier rate and sentiment backdrop: Beaten-down, cash-generative software names tend to re-rate higher as rates fall and money rotates back toward growth.
What's the most you can lose? The premium paid. Nothing more. Defined-risk. This matters here because there is no price stop, so the premium is the entire amount at risk. Do not size it as anything other than fully losable.
When does this trade stop making sense? If (1) customer expansion keeps drifting (net retention, the rate at which existing customers grow their spend, falls below ~105% and heads toward 100%), (2) net new recurring revenue decelerates for two or more quarters, (3) stock-based pay stops falling as a share of revenue while buybacks slow (the cash-flow-quality gap stops closing), or (4) the stock is underwater and the story has changed as expiry approaches (do not ride a broken thesis into the final months).
Valuation Summary
Scenario
Fair Value Range (per share)
vs ~$10.20 (June 24)
Conservative
$13 - $16
+27% to +57%
Base
$15 - $20
+47% to +96%
Bull
$19 - $26
+86% to +155%
Caveat: These ranges use UiPath's reported (adjusted) free cash flow, which adds back nothing for stock-based pay. That pay is a real cost. Charged in full, the same model lands near $8-$10 (base), with a blended honest fair value around $9.43, just below today's ~$10.20. So the value cushion under the $10 strike is real on reported cash flow and roughly fair-to-marginal on a stock-comp-burdened basis. The $10 strike sits below the entire reported-FCF range and brackets the honest base case, so there is a floor on reported cash flow and the upside leans on the re-rating, not on a discount today. See Section 4.
Analyst Price Targets
Metric
Value
Average target
~$13.30 to ~$14.14 (depending on the aggregator)
Median target
~$13.44
Range
~$10 to ~$19
Consensus rating
Hold (~14 analysts; a growth-rate debate, not a quality or solvency one)
Implied upside from ~$10.20
~+30% to ~+39% to the average
Even the cautious targets sit near or above the current price, consistent with the cash-anchored downside. The split among analysts is about how fast growth reaccelerates, not about whether the company survives.
Notable Analyst Price Targets
Analyst / Firm
Rating
Price Target
Notes
RBC Capital
Buy
$19
Most recent high-end update
Morgan Stanley
Overweight
$17
Street high in consensus
BofA Securities
Neutral
$13
Raised from $12
DA Davidson
Neutral
$12
Lowered from $13
Truist
Hold
$12
Near Street low
Needham
Buy
n/a
Upgraded to Buy after Q4
Key Dates & Numbers
Item
Detail
Strike price
$10
Expiration
January 21, 2028
Breakeven at expiration
~$10 + premium (TBD on live chain)
Current stock price
~$10.20 (June 24, 2026)
52-week range
$9.20 - $19.84
Next earnings
~Sept 3, 2026 (Q2 FY2027); roughly six reports before expiry
FY2027 revenue guidance
$1.776B - $1.781B (~10% YoY)
FY2027 ARR guidance
$2.058B - $2.063B (~11% YoY)
Net cash
~$1.42B (~$2.70/share, no debt)
Stop loss
None (by choice; defined-risk, hold to exercise or sell)
Take profit
Scale out at price targets (~$15-16 first trim, ~$19-20+ material trim)
Days to expiration
~575 (~19 months)
Where to Find More Detail
Section 2 (Overall Assessment) - Conviction and key dependencies.
Section 3 (Risk Management) - Why no price stop, the thesis stop, price-target scale-out, exercise-or-sell plan.
Section 6 (Strike Structure) - Why $10 and how the premium behaves.
Section 7 (Key Risks) - Value trap, stock-comp dilution, competition, no stop.
2️⃣ Overall Assessment
A slightly-in-the-money LEAP on a profitable, net-cash software business the market still prices like a failed IPO. The quality is real; the open question is whether modest growth reaccelerates.
The $10 strike sits below the entire reported-FCF fair-value range ($13-$20 base) and brackets the honest, stock-comp-burdened base (~$8-$10). On reported cash flow the call is backed by value before it has to move at all; on the stricter honest view it is roughly fair.
The structure tracks the shares with a defined maximum loss, which is the lower-risk way to express a long-run, "grow into the valuation" view, and it is built to either exercise into shares or sell.
The main risk is not a crash but dead money: a 19-month option still expires, so a flat stock that never breaks above the low teens can still cost most of the premium even though the business never broke.
Conviction level: Medium. The value support and ~$2.70/share net-cash floor are real, the structure is conservative for an option (long-dated, slightly in the money, value underneath), and the long runway spans about six earnings reports. Held below High because growth has not yet inflected, the stock-comp-burdened view makes the equity only fair at today's price, and value-trap risk is live. This is not Speculative either: the structure is the opposite of aggressive.
Key dependencies: Organic net new recurring revenue reaccelerating (or at least stabilizing), customer expansion holding above ~105%, stock comp continuing to fall as a share of revenue, and the multiple not de-rating further regardless of execution.
3️⃣ Risk Management & Exit Framework
Position parameters
Stop loss: NONE, by choice. This is a long-run, defined-risk hold built to exercise or sell. The most that can be lost is the premium, and a percentage stop on a volatile, slightly-in-the-money 19-month LEAP would likely trigger on routine noise well before the thesis plays out. Size the position as money you are willing to lose entirely.
Take profit: scale out at price targets. Trim a portion as the stock works toward ~$15-$16, trim materially at ~$19-$20+, and keep a core sleeve for the long run. If UiPath keeps executing, exercise the remaining calls into shares near expiry rather than selling, to build a permanent holding.
Replacing a price stop with a thesis stop is the deliberate trade-off here: no forced exit on volatility, but a hard rule to leave if the business actually breaks.
Thesis-based exit (this replaces the stop)
Exit if net retention drops below ~105% and heads toward 100%, or if net new recurring revenue keeps decelerating for two or more quarters. At that point the growth-optionality reason to hold is gone, and a decaying option on a broken thesis is just hoping.
Reassess hard as expiry nears: if the stock is underwater and the story has changed, do NOT ride it into the final months. Decide to exercise, sell, or walk away well before theta accelerates.
Other rules
Do not average down to "fix" a losing LEAP. Add only to a working thesis, and do it in the shares at better prices, not by stacking more premium into the option.
Time decay (theta) is gentle early and accelerates in the final ~3 months. Plan the exercise-or-sell decision before then, not after.
No plan to trade around earnings; this is a hold, so the premium drop after a report (IV crush) is a minor background factor here, not an exit trigger.
4️⃣ Valuation Assessment
Inputs:
Price (June 24, 2026): ~$10.20
Shares outstanding: ~520M (diluted; to confirm against the latest 10-Q)
Stock-based compensation (FY2026): ~$207M (to confirm against the 10-K cash-flow statement)
SBC-adjusted (owner) FCF: ~$165M
Net cash: ~$1.42B (no debt)
Forecast method: Two-stage (years 1-5, then 6-10) plus a terminal value
Discount rates: 9-11%
Terminal growth: 3-4%
Plain terms: A DCF (discounted cash flow) estimates today's value by projecting future free cash flow (the cash left after running and investing in the business) and discounting it back to today.
Important caveat (read first): UiPath reports "adjusted" free cash flow that adds back stock-based pay (~$207M in FY2026). That is a real cost: it transfers ownership from shareholders to employees. The tables below use the reported figure, so they flatter the economics. On a stock-comp-burdened base (owner cash nearer $165M), fair values are far lower: base around $8-$10, with a blended honest value of ~$9.43. The honest read: PATH is cheap if reported cash flow is real owner cash, and only fair if stock comp is charged in full. Stock comp is falling as a share of revenue (dilution guided toward 2-3%), so the two views should converge over time.
Historical FCF (what informed the growth rates)
Fiscal Year (ends Jan 31)
Adjusted FCF ($M)
YoY
Revenue ($B)
FCF margin
2024
~298 (approx)
-
1.31
~23%
2025
328
+10%
1.43
~23%
2026
372
+13%
1.61
~23%
Adjusted-FCF growth has tracked revenue (~12% over FY2024-FY2026), not exceeded it. The big absolute step-up happened earlier (a one-time efficiency reset), and margin has since flattened near 23%. This is not a margin-expansion story going forward, so growth is modeled off revenue, not off rising margins.
Bull (15%) roughly continues recent revenue growth with a small further margin gain. Base (10%) steps growth toward guidance, fading to mid-single digits. Conservative (5%) stresses growth toward the low single digits with flat margins.
Charging the full ~$207M of stock-based pay as a cash cost (owner FCF ~$165M, no buyback credit) drops fair value sharply:
Scenario
Honest Fair Value / Share
vs ~$10.20 (June 24)
Conservative
~$7 - $9
-31% to -12%
Base
~$8 - $10
-22% to -2%
Bull
~$10 - $13
-2% to +27%
Blended honest fair value: ~$9.43 (-8% vs ~$10.20). The buyback (~$329M in FY2026 plus a new $500M authorization) more than offsets share-count dilution but consumes the very cash the business generates, so it is treated as a qualitative floor here, not netted into the value.
Strike Positioning
The $10 strike sits below the entire reported-FCF range (conservative low ~$13), so on reported cash flow the call is backed by value before it has to move at all.
On the honest, stock-comp-burdened basis it sits inside the base case (~$8-$10) and just below the blended ~$9.43, so it is roughly fair rather than cheap on that stricter view.
Either way this is the opposite of a momentum-only call: there is a cash-anchored floor (~$2.70/share net cash) under the equity beneath the strike.
Growth Stress Test (critical)
Base assumes 10% Stage 1 growth. Halve it to 5% and the base reported-FCF fair value still lands around $14 at a 10% discount, above the strike. The reported-FCF valuation is not very sensitive to growth, because cash and the low multiple dominate.
That is exactly why the stock-comp question matters more than the growth question here. Rerun the model on burdened cash flow and the blended value falls to roughly $9.43, near today's price; halving the honest base growth pulls it toward ~$8 (about 20% below today). If the market ever prices PATH on the honest cash flow, the LEAP needs the agentic re-rate to do the work.
SBC note: Stock-based pay is ~$207M, roughly 56% of reported free cash flow, which is very high and load-bearing to this thesis. That is why the full SBC-adjusted view above is shown rather than a one-line note: the honest cash flow is the number that decides whether the strike has a real cushion under it.
5️⃣ Catalyst Thesis
Earnings (Q2 FY2027, ~Sept 3). The next read on whether growth stabilizes or keeps drifting. Q1 (reported late May) beat on revenue (+17%) and delivered the first profitable first quarter in company history, but net new recurring revenue was about $49M and net retention was roughly 107-108% once currency and acquisitions are stripped out. Watch organic net new recurring revenue and retention, not the headline revenue number.
Agentic-AI conversion. The swing factor. AI is showing up in the bulk of the large deals, and AI-attached expansion deals have reportedly run far larger than those without. UiPath is repositioning from "software robots" to orchestrating AI agents, robots, and people together through its Maestro product. If that pulls recurring-revenue growth and customer expansion back up, the market would likely value the whole company more generously.
Buybacks. UiPath completed a $1B repurchase program and authorized another $500M, buying shares at depressed prices. Buybacks matter doubly here because they offset the dilution from paying staff in stock.
AI partnerships. Integrations with Microsoft, OpenAI, NVIDIA, Snowflake, and Databricks, plus an expanded Deloitte alliance for "agentic ERP," position UiPath as the enterprise plumbing that puts frontier-model capability to work and governs it. This drives the re-rate leg, not the base demand.
Rate and sentiment backdrop. Beaten-down, cash-generative software tends to re-rate higher as rates fall and money rotates back toward growth. With the stock near the bottom of its 52-week range, a single clean print could start to reverse the negative sentiment cycle.
6️⃣ Strike Structure
Strike: $10. Breakeven at expiration: ~$10 + premium (TBD on the live chain). Required move: none to reach the strike (already slightly in the money), more to clear breakeven if held to expiry.
Estimated delta: TBD from the live chain. A slightly-in-the-money 19-month call will likely carry a fairly high delta, tracking the shares closely. Days to expiration: ~575.
How the premium behaves:
Delta (sensitivity). Each $1 rise in PATH lifts the premium by the delta amount, and because the call is already in the money that sensitivity is already meaningful, growing further as the stock rises.
Vega (volatility). The premium also moves with demand for options. On a long-dated LEAP this is a slow background factor, not something to trade around.
Theta (time decay). Works against you daily but is gentle at ~575 days and only accelerates in the final months. That gentle early decay is what makes a buy-and-hold LEAP viable where a short-dated call would bleed out.
Because it is already past the strike, the path to profit is the stock grinding up through breakeven over the hold, not a sprint to a far-off strike before time runs out. At expiry the choice is simple: exercise into shares if the thesis is intact, or sell the call.
7️⃣ Key Risks
Value trap / dead money (the main risk). A LEAP expires; shares do not. If modest growth never reaccelerates and the stock sits at $10-$12 into Jan 2028, the option bleeds its time value and can finish near breakeven or worse even though the business never broke. This is the dominant risk.
Stock-comp dilution and FCF quality. The cheap-looking metrics rest on reported cash flow that ignores ~$207M of stock-based pay (about 56% of FCF). On the honest basis the stock is only fair at today's price, which caps how much real value cushion sits under the strike.
Customer expansion has not inflected. Net retention is ~107-108% and roughly flat. The hoped-for turn has not yet shown up in the organic numbers.
Competition and a crowded market. Microsoft, Automation Anywhere, and AI-native startups compete directly, and the same frontier labs UiPath partners with could move into its territory.
Insider selling. The founder-CEO and other executives have sold shares under pre-scheduled plans during the slide, a sentiment negative worth monitoring.
No stop. By design, there is no forced exit on a falling price, so the whole premium is at risk if the thesis breaks and the thesis stop is ignored.
Counter-argument (why this can work): UiPath is profitable, debt-free, and sits on ~$1.42B of net cash (~$2.70/share), the $10 strike is below the entire reported-FCF fair-value range and the call is already slightly in the money, time decay is gentle for most of the hold, and if the agentic pivot reaccelerates growth even modestly, a cheap, cash-rich software name can re-rate well above the strike with plenty of time to spare, at which point the calls can be exercised into a permanent holding.
Research for personal use. Not investment advice. Options can expire worthless and the entire premium is at risk. Verify pricing, the live option chain (premium, delta, breakeven, implied volatility), share count, net cash, and any catalyst developments through primary sources before any transaction. The DCF is a scenario tool, not a prediction; small changes in growth and discount-rate assumptions move fair value a lot, and the gap between the reported and SBC-adjusted views is unusually large for this name.